Activated monocytes kill malignant brain tumor cells in vitro

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Investigating novel therapeutic strategies to enhance anti-tumor immunity is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy of human peripheral-blood monocytes, activated by biological response modifiers (BRMs), in lysing human glioblastoma cells.
• To compare the direct cytotoxic effects of various BRMs on tumor cells.

Main Methods:

• Human peripheral-blood monocytes were activated in vitro using gamma-interferon (IFN), beta-interferon (IFN), lipopolysaccharide (LPS), muramyldipeptide (MDP), and tumor necrosis factor-alpha (TNF-alpha).
• Activated monocytes and BRMs were co-cultivated with radiolabeled human glioblastoma cell lines, a brain metastasis cell line, and a melanoma cell line.
• Cytotoxicity was quantified after 72 hours of co-cultivation.

Main Results:

• Monocytes activated with beta-IFN and TNF-alpha demonstrated significant lysis of brain tumor cell lines.
• Combinations of BRMs, particularly gamma-IFN + beta-IFN and gamma-IFN + TNF-alpha, enhanced monocyte-mediated lysis.
• Monocyte-mediated cytotoxicity was up to tenfold higher than direct BRM cytotoxicity.

Conclusions:

• BRM-stimulated peripheral-blood monocytes exhibit potent in vitro cytotoxic activity against human glioblastoma cells.
• Combined BRM stimulation enhances monocyte-mediated tumoricidal activity, suggesting synergistic mechanisms.
• These findings highlight the potential of immunomodulatory therapies for glioblastoma treatment.